Besides, the structure of the active ingredient diosmectite in Smecta is capable of absorbing other drugs and excreted if used together. Smecta Sachet Powder is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: Do not use this medication for a long time without your doctor's advice: examinations may be necessary if symptoms persist. You should always take this medication exactly as prescribed in this leaflet or by your doctor or pharmacist. WHAT IS SMECTA 3 g ORANGE-VANILLA, powder for oral suspension in sachets AND WHAT CASES IS IT USED FOR?

What is SMECTA 3 g ORANGE-VANILLA, powder for oral suspension in sachets and in which cases it is used? An allergic reaction that can manifest itself by the following signs: redness of the skin, itching, swelling of the face and throat, difficulty breathing, malaise, collapse. The drug does not cause a contrast effect, does not change the color of the stool, does not change the physiological transit time in the intestine if used in normal doses. Despite significantly shorter time to recovery in the diosmectite group, the proportions of patients achieving recovery were similar in both groups at the end of the study. This is explained by acute watery diarrhoea being self-resolving within seven days. Do not throw any medicines into drains or rubbish. Ask your pharmacist to remove any medications you are no longer using. These measures will help protect the environment.

The substances contained in this medication are poorly absorbed. However, do not use it for a prolonged period during pregnancy or breastfeeding without the advice of your doctor or pharmacist. Smecta drug works by the mechanism of penetration correlated with the mucous membranes forming a protective armor layer to protect the intestinal tract and prevent bacteria from invading. Therefore, the drug offers the following uses: Absolutely do not give Smecta medicine to children with milk, but you can also mix Smecta with sugar water. The trial was performed in a homogeneous Tunisian population with positive stool culture in 26% of the patients. These figures are consistent with those reported in the literature and previously in Tunisia [ 4, 6, 23, 25]. Of note is that most patients had a recent episode of acute diarrhoea, similar in both groups (median time from first watery stool to treatment onset = 1 [0–3] day from the 1st watery stool to inclusion (NS)), with at least one associated symptom such as nausea, abdominal pain, or anal irritation in >90% of the patients and a median number of six stools per day before treatment onset. Hence, it can be extrapolated that if the primary endpoint variable had been measured from the time of onset of diarrhoea, instead of from the first intake of study drug, the difference between the two groups would still have been the same, that is, 15.2 hours. Moreover, this pattern of diarrhoea is in accordance with the definition of acute diarrhoea in developed countries [ 4, 25, 26]. Therefore, it can be estimated that results of the present study can be extrapolated to western countries.

Acute diarrhoea is one of the leading causes of morbidity worldwide [ 1]. The annual rate of diarrhoea among adults in Western Europe and the United States averages about one episode per person per year [ 2– 4]. Episodes are usually brief, not life-threatening and most often self-limited but symptoms can be disturbing and incapacitating. Urgency, loose stools, abdominal discomfort, and inconvenience such as loss of faecal continence make it an unpleasant and distressing condition. It is commonly recognized that these symptoms lead to substantial costs for society as it is estimated that half of the episodes are related to missed workdays [ 5, 6]. No studies on the ability to drive and use machines have been performed. However, the expected effect is nil or negligible. The statistical analysis plan was based upon the assumption that the duration of the diarrhoea episode would be shorter than seven days for all patients, without any risk of data censure. It was therefore planned to compare mean diarrhoea durations using the Wilcoxon's test, which is perfectly adapted to this type of data. The definition of diarrhoea duration required that patients are followed after the first formed stool to confirm the end of the diarrhoea episode. This definition of recovery was selected to guarantee the clinical relevance of the primary criterion. Of note is that it was much more constraining than previous trials, which defined recovery as the first nonliquid stool. However, according to the definition of recovery used in the study, 35 patients showed diarrhoea duration longer than seven days. Since the protocol planned a seven-day followup, these patients were censored in statistical analyses. Nevertheless, a post hoc time to event analysis taking data censure into account was carried out. The Gehan-Wilcoxon test was preferred to the Logrank test because of the particular distribution of the events considered and the onset of censures during study followup. Indeed, the Gehan-Wilcoxon test is more adapted than the Logrank test to early events and late censures. Moreover the latter is based upon the assumption of proportional hazards, which is most probably not verified in this trial since the active treatment is supposed to shorten time to recovery without modifying the risk of recovery. Acute watery diarrhoea is self-resolving, even in the absence of treatment. The results of the Gehan-Wilcoxon test confirmed the effectiveness of diosmectite. These results are consistent with the primary analysis and confirm that diosmectite shortens time to recovery. The endpoints most frequently used in trials regarding antidiarrhoeal drugs in children and adults are stool volume and time from treatment onset to last liquid or first formed stool [ 12, 14, 26, 27]. Except in chronic diarrhoea, trials performed in adults rarely use stool volume as an endpoint. The clinical effect of diosmectite as an antidiarrhoeal agent in adults has been assessed mainly by the measurement of time to transit normalization [ 6, 26]. The definition of recovery chosen is again more stringent since it is based not only on the achievement of a normal stool but also by its following a nonwatery stool, thereby reflecting an actual cessation of the acute diarrhoea episode.Smecta Sachet Powder is used for Acute and chronic diarrhea, Irritable bowel syndrome in adults, Gastroesophageal reflux in infant and other conditions. Natural reaction of the organism against an element recognized as foreign. It manifests itself locally by redness, heat, pain or swelling.